Alzheimer's Dementia

AriBio USA Inc. announced the enrollment of the first participants in a phase 3 trial to evaluate the efficacy of a novel therapeutic to treat those with early Alzheimer’s disease.

A biopharmaceutical company and the Miller School of Medicine at the University of Miami have announced a partnership to conduct a phase 1/2a clinical trial of ALZN002, a treatment for Alzheimer’s-related dementia.

Dementia prevalence dropped 3.7 percentage points in the U.S. from 2000 to 2016, according to a RAND Corporation study published in Proceedings of the National Academy of Sciences.

A practical risk score tool has been developed to help people identify their potential risk for dementia, researchers reported in JAMA Network Open.

MediCane Health Inc. announced recruitment of the first patient for its phase 2a study designed to assess the effects of cannabis oil in adults with probable Alzheimer’s disease who have limited or no response to antipsychotic medication.

In this edition, preventive therapies should be offered for migraines; targeting neuropathic symptoms for poststroke pain; PDE5 inhibitors not associated with lower AD, dementia risk and more.

Although it was well tolerated, the anti-amyloid antibody crenezumab did not reduce clinical decline in patients with Alzheimer's disease, researchers reported in JAMA Neurology.

Those with amnestic mild cognitive impairment who used the BrainHQ app for visual speed and attention exercises improved neuropsychological measures of speed, attention, memory and connectivity.

In this week's edition, the FDA approval of a transdermal patch to treat Alzheimer’s-related dementia; the link between daily napping and an increased risk for Alzheimer’s disease; an oral treatment for Parkinson’s; and more.

Amyloid load appeared to negatively influence the progression of self-esteem among people at risk for Alzheimer’s dementia, according to study results published in Journal of Clinical Psychiatry.